Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
Federica MigliettaMaria Vittoria DieciVassilena TsvetkovaGaia GriguoloGrazia VernaciAlice MenichettiGiovanni FaggioniTommaso GiarratanoEleonora MioranzaElisa GenovesiEnrico CumerlatoMichele BottossoTania SaibeneSilvia MichielettoMarcello Lo MelePierfranco ConteValentina GuarneriPublished in: The oncologist (2020)
The present work validated residual proliferative cancer burden (RPCB) as a strong predictor of long-term outcome in patients with hormone receptor-positive human epidermal growth receptor 2-negative (HR+/HER2-) breast cancer (BC) treated with neoadjuvant chemotherapy. In addition, results from the present study suggest RPCB as a promising tool to identify patients with HR+/HER2- BC who might potentially benefit from the inclusion in clinical trials evaluating novel or escalated postneoadjuvant treatment strategies because it allowed to discriminate a subgroup of patients with particularly poor prognosis despite having received subsequent endocrine therapy in the adjuvant setting.
Keyphrases
- neoadjuvant chemotherapy
- poor prognosis
- locally advanced
- endothelial cells
- lymph node
- papillary thyroid
- sentinel lymph node
- clinical trial
- long non coding rna
- squamous cell
- induced pluripotent stem cells
- pluripotent stem cells
- rectal cancer
- childhood cancer
- early stage
- squamous cell carcinoma
- randomized controlled trial
- stem cells
- young adults
- lymph node metastasis
- wound healing
- risk factors
- binding protein
- phase iii
- replacement therapy